C Diff Drug Development

C Diff Drug Development

997 bookmarks
Custom sorting
Recursion Advances AI-Based C. Diff Candidate to Phase II
Recursion Advances AI-Based C. Diff Candidate to Phase II
REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract.
·genengnews.com·
Recursion Advances AI-Based C. Diff Candidate to Phase II
Global Clostridium Difficile Infections Treatment Market Set to Reach USD 1,448.75 Million by 2033,
Global Clostridium Difficile Infections Treatment Market Set to Reach USD 1,448.75 Million by 2033,
Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is poised for significant growth over the next decade. Valued at an impressive USD 809 million in 2023, the market is projected to expand at a robust Compound Annual Growth R...
·pharmiweb.com·
Global Clostridium Difficile Infections Treatment Market Set to Reach USD 1,448.75 Million by 2033,
AZD-5418 protects from C. difficile colonic damage
AZD-5418 protects from C. difficile colonic damage
Clostridioides difficile, a spore-forming and anaerobic gram-positive bacterium, causes a wide-spectrum diarrheal disease that can ultimately lead to life-threatening conditions such as toxic megacolon or colonic perforation.
·bioworld.com·
AZD-5418 protects from C. difficile colonic damage
New mRNA Vaccine Could Tackle Antibiotic Resistant C. difficile Infections
New mRNA Vaccine Could Tackle Antibiotic Resistant C. difficile Infections
Bacteria Striking Back Bacterial infections are much less deadly than they used to be before the introduction of antibiotics. “Before we had antibiotics, infections like scarlet fever could even lead to heart problems. Surgery often led to deadly infections in the blood like bacteremia or septicemia. A World Without Antibiotics Because antibiotics silently save so […]
·securities.io·
New mRNA Vaccine Could Tackle Antibiotic Resistant C. difficile Infections
Health rounds mrna vaccine shows promise against c difficile animal study 2024 10 18
Health rounds mrna vaccine shows promise against c difficile animal study 2024 10 18
Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind the revolutionary mRNA vaccines that tackled the coronavirus that caused COVID-19.
·reuters.com·
Health rounds mrna vaccine shows promise against c difficile animal study 2024 10 18
Penn Medicine researchers create 1st mRNA C. diff vaccine
Penn Medicine researchers create 1st mRNA C. diff vaccine
Discover the groundbreaking mRNA vaccine developed by University of Pennsylvania and Children's Hospital of Philadelphia to prevent and treat C. difficile
·beckershospitalreview.com·
Penn Medicine researchers create 1st mRNA C. diff vaccine
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.
·pubmed.ncbi.nlm.nih.gov·
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
New mRNA vaccine created to prevent and treat C. difficile
New mRNA vaccine created to prevent and treat C. difficile
A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. The results will pave the way for clinical trials of the vaccine.
·sciencedaily.com·
New mRNA vaccine created to prevent and treat C. difficile
Repurposing of monocyclic β-lactams as anti-inflammatory agents - The case of new ferrocene-azetidin-2-one hybrids - PubMed
Repurposing of monocyclic β-lactams as anti-inflammatory agents - The case of new ferrocene-azetidin-2-one hybrids - PubMed
There is growing interest in developing monotherapy drugs that treat inflammation caused by microbial infections, focusing on dual antimicrobial and anti-inflammatory agents with minimal side effects and high safety margins. This study synthesized and characterized a library of novel cis-4-ferroceny …
·pubmed.ncbi.nlm.nih.gov·
Repurposing of monocyclic β-lactams as anti-inflammatory agents - The case of new ferrocene-azetidin-2-one hybrids - PubMed
A novel mRNA-LNP vaccine facilitates Clostridioides difficile control
A novel mRNA-LNP vaccine facilitates Clostridioides difficile control
Clostridioides difficile is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.
·bioworld.com·
A novel mRNA-LNP vaccine facilitates Clostridioides difficile control
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.
·pubmed.ncbi.nlm.nih.gov·
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial - PubMed
Nestlé agrees to buy microbiome therapy Vowst from Seres
Nestlé agrees to buy microbiome therapy Vowst from Seres
Seres Therapeutics (NASDAQ:MCRB) announced Tuesday that Nestlé Health Science, a unit of consumer care giant Nestle (OTCPK:NSRGY), has agreed to purchase its oral microbiome therapy Vowst for $175M. However, shares of the Cambridge, Massachusetts-based biotech fell ~21% in reaction. Developed by Seres (MCRB) and Nestlé Health Science, Vowst was app...
·msn.com·
Nestlé agrees to buy microbiome therapy Vowst from Seres
Scientists develop mRNA vaccine that protects mice against intestinal C. difficile bacteria
Scientists develop mRNA vaccine that protects mice against intestinal C. difficile bacteria
A large team of microbiologists, pathologists and infectious diseases specialists affiliated with several institutions in the U.S. has developed an mRNA vaccine that has thus far been found able to protect mice against intestinal Clostridioides difficile bacterial infections.
·msn.com·
Scientists develop mRNA vaccine that protects mice against intestinal C. difficile bacteria
Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile
Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile
Clostridium difficile (C. difficile) is one of the most threatening bacteria globally, causing high mortality and morbidity in humans and animals, and is considered a public health threat that requires urgent and aggressive action. Interruption of the human gut microbiome and the development of anti
·pubs.rsc.org·
Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile